← 返回

重楼增强麦门冬汤抗肺癌转移的疗效

英文原题:Paris polyphylla enhances the anti-metastatic efficacy of maimendong decoction against lung cancer.

查看英文原题

Paris polyphylla enhances the anti-metastatic efficacy of maimendong decoction against lung cancer.

PubMed 2025/12/22(内容时间) Biol Proced Online Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

将重楼纳入 MMDD 可通过双重机制增强其抗转移疗效:直接诱导肺癌细胞凋亡,并通过增加 CD8+ T 细胞的丰度和细胞毒性功能来放大抗肿瘤免疫。MMDD + P.P 与抗 PD-1 抗体治疗之间的协同作用凸显了这种改良中药方剂作为抑制肺癌转移的有前景辅助治疗的潜力。

研究思路结论见上方概要

麦门冬汤(MMDD)是治疗肺痿的经典中药方剂,对多种肺部疾病具有疗效。我们前期研究证实,MMDD通过调节自然杀伤(NK)细胞抑制肺癌转移。重楼(P.P)是一种已知具有抗肿瘤特性的中药,常被加入经典方剂中以增强治疗效果。本研究旨在通过加入重楼(Paris polyphylla)来增强MMDD对肺癌的抗转移疗效,并探讨其潜在机制。

加味麦门冬汤(MMDD + P.P)通过加入9 18 g七叶一枝花制备而成。采用CCK-8、Transwell和Annexin V-FITC/PI流式细胞术检测其对CTC-TJH-01和LLC细胞增殖、迁移和凋亡的影响。通过Western blot分析凋亡相关蛋白。建立C57BL/6小鼠尾静脉注射诱导的肺转移模型,以评估MMDD + P.P单独及联合anti-PD-1抗体对转移的影响。采用流式细胞术分析外周血中T细胞和NK细胞群体。使用H&E染色、免疫组化(针对Ki-67和cleaved caspase-3)和免疫荧光(针对CD8+ T细胞和NK细胞浸润)对转移组织进行组织学和分子分析。

与单用MMDD相比,MMDD + P.P(18 g)显著抑制了CTC-TJH-01和LLC细胞的增殖和迁移,并诱导其凋亡。这些效应与促凋亡蛋白(cleaved caspase-3、BAX、cleaved PARP)的上调以及抗凋亡蛋白(BCL-2、Survivin)的下调相关。在体内,虽然MMDD和MMDD + P.P均减少了肺转移结节的数量,但MMDD + P.P(18 g)独特地显著降低了总体肿瘤负荷,这与转移灶中Ki-67的减少和cleaved caspase-3的增加相关。此外,MMDD + P.P(18 g)显著增加了NK细胞和CD8+ T细胞的比例及肿瘤浸润。它还与anti-PD-1治疗产生协同作用,增强了后者的抗转移效果,并提高了CD8+ T细胞中细胞毒性标志物(CD107a、perforin、granzyme B)和TNF-的表达。

展开英文摘要原文

Maimendong decoction (MMDD), a classic traditional Chinese medicine (TCM) formula prescribed for lung atrophy , has demonstrated efficacy against various pulmonary disorders. Our prior research confirmed that MMDD inhibit lung cancer metastasis by modulating natural killer (NK) cells. Paris polyphylla (P.P), a TCM herb with known anti-tumor properties, is often incorporated into classic formulas to enhance therapeutic outcomes. This study aimed to boost the anti-metastatic efficacy of MMDD against lung cancer by incorporating Paris polyphylla (Chonglou) and to investigate the underlying mechanisms.

The Modified Maimendong Decoction (MMDD + P.P) Was Prepared by Adding 9 18 g of Paris polyphylla. Its Effects on the proliferation, migration, and Apoptosis of CTC-TJH-01 and LLC Cells Were Assessed Using CCK-8, Transwell, and Annexin V-FITC/PI Flow Cytometry assays. Apoptosis-related Proteins Were Analyzed by Western blot. A Tail Vein injection-induced Lung Metastasis Model in C57BL/6 Mice Was Established To Evaluate the Effects of MMDD + P.P, both Alone and in Combination with an anti-PD-1 antibody, on Metastasis Flow cytometry was used to profile T cell and NK cell populations in peripheral blood. Histological and molecular analyses of metastatic tissues were performed using H&E staining, immunohistochemistry (for Ki-67 and cleaved caspase-3), and immunofluorescence (for CD8+ T cell and NK cell infiltration).

Compared to MMDD alone, MMDD + P.P (18 g) significantly inhibited proliferation and migration, and induced apoptosis in both CTC-TJH-01 and LLC cells. These effects were associated with the upregulation of pro-apoptotic proteins (cleaved caspase-3, BAX, cleaved PARP) and downregulation of anti-apoptotic proteins (BCL-2, Survivin). In vivo, while both MMDD and MMDD + P.P reduced the number of lung metastatic nodules, MMDD + P.P (18 g) was uniquely effective in significantly reducing overall tumor burden, which correlated with decreased Ki-67 and increased cleaved caspase-3 in metastatic foci. Furthermore, MMDD + P.P (18 g) significantly increased the proportions and tumor-infiltration of NK cells and CD8+ T cells. It also synergized with anti-PD-1 therapy, enhancing its anti-metastatic effect and boosting the expression of cytotoxic markers (CD107a, perforin, granzyme B) and TNF- in CD8+ T cells.

Incorporating Paris polyphylla into MMDD enhances its anti-metastatic efficacy through a dual mechanism: directly inducing apoptosis in lung cancer cells and amplifying anti-tumor immunity by increasing the abundance and cytotoxic function of CD8+ T cells. The synergy between MMDD + P.P and anti-PD-1 antibody therapy highlights the potential of this modified TCM formula as a promising adjunctive treatment for inhibiting lung cancer metastasis.

论文信息

作者
Zhang Z、Li J、Shi W、Que Z、Yao W、Yao J、Shangguan W、Zhu W
第一作者单位
Clinical Oncology Center Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.China
通讯作者单位
Clinical Oncology Center Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China. tjhhawk@163.com.China
期刊
Biological procedures online2025 Dec 22
原文标识
PubMed 41430561 · DOI 10.1186/s12575-025-00317-x